To analyze this possibility, we first evaluated if there was an association between the presence of a JAK2 mutation and thrombotic event in patients with ET, PMF, and SMF post-ET (n=44 patients with information available about thrombotic events). Here, JAK2 is linked to essential thrombocythemia.